New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
August 11, 2014
11:04 EDTAUXL, BSX, KMR, TITN, TKMR, NOAH, SWIActive equity options trading on open
High option volume stocks: TKMR KMR SWI TITN BSX KMI DF NOAH AMLP AUXL
News For AUXL;TKMR;KMR;SWI;TITN;BSX;NOAH From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
December 19, 2014
07:38 EDTBSXBoston Scientific risk/reward favorable after trial ends, says Wells Fargo
Subscribe for More Information
December 16, 2014
16:53 EDTAUXLAuxilium updates court findings in Actavis testosterone gel patent suit
Auxilium (AUXL) disclosed in a filing that as previously disclosed, on May 23 , Auxilium Pharmaceuticals, and FCB I LLC, as licensor of Testim, filed a lawsuit in the U.S. District Court for the District of New Jersey against Actavis (ACT) for infringement of FCBís 10 patents listed in the Orange Book as covering Testim testosterone gel. The lawsuit was filed in response to a notice letter, dated April 12, 2012, sent by Actavis Laboratories, regarding its filing with the U.S. Food and Drug Administration of an Abbreviated New Drug Application for a generic 1% testosterone gel product. This letter also stated that the ANDA contained Paragraph IV certifications with respect to the nine patents listed in the Orange Book on that date as covering Testim. The companyís lawsuit filed against Actavis initially involved those nine patents, as well as a 10th patent covering Testim that was issued on May 15, 2012 and is listed in the Orange Book. By the time that the trial commenced in September 2014, the parties had agreed to remove all but one of those patents from the litigation, with the trial focused solely on claim 3 of U.S. Patent # 7,608,607 . The trial commenced in September 2014 and closing arguments occurred in November 2014. On December 16 , the company learned that Judge Linares held that claim 3 of the Ď607 patent is invalid for obviousness. The Judge also found claim 3 invalid for derivation and improper inventorship, but he declined to rule on whether correction of inventorship would be appropriate because it would be futile in light of his ruling on obviousness. Auxilium believes that Actavis is now free to enter the market with its testosterone gel product once it obtains approval from the FDA. At this time, Auxilium is not aware of Actavis having received tentative approval or final approval from the FDA for its testosterone gel product. Auxilium is analyzing the District Courtís opinion and will explore its available options with regard to this matter.
08:58 EDTAUXLEndo a top pick for 2015, says Sterne Agee
Subscribe for More Information
December 12, 2014
09:02 EDTBSXBoston Scientific presents data of Precision Spinal Cord Stimulator system
Subscribe for More Information
December 11, 2014
17:04 EDTAUXLEndo registration statement relating to Auxilium declared effective by SEC
Subscribe for More Information
December 10, 2014
07:38 EDTBSXBoston Scientific management to meet with Deutsche Bank
Subscribe for More Information
06:52 EDTTITNTitan Machinery lowers 2015 adjusted EPS view to 10c-30c from 30c-60c
Consensus is 40c. Lowers 2015 revenue view to $1.85B-$2.0B from $1.9B-$2.1B, consensus $2.05B.
06:50 EDTTITNTitan Machinery reports Q3adjusted EPS 14c, consensus 20c
Subscribe for More Information
06:01 EDTBSXBoston Scientific implied volatility of 38 at upper end of index mean range
December 9, 2014
10:27 EDTBSXOptions with increasing implied volatility
Subscribe for More Information
December 8, 2014
10:42 EDTBSXOptions with increasing implied volatility
Subscribe for More Information
10:11 EDTNOAHHigh option volume stocks
Subscribe for More Information
05:53 EDTBSXStocks with implied volatility movement; BSX BMY
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use